{"id":45328,"date":"2025-10-30T22:14:55","date_gmt":"2025-10-30T14:14:55","guid":{"rendered":"https:\/\/flcube.com\/?p=45328"},"modified":"2025-10-30T22:14:56","modified_gmt":"2025-10-30T14:14:56","slug":"bayer-secures-fda-approval-for-elinzanetant-first-dual-nk-therapy-for-vms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45328","title":{"rendered":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS"},"content":{"rendered":"\n<p>Bayer (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced that the U.S. Food and Drug Administration had granted marketing approval for <strong>elnizanetant<\/strong>, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as <strong>Lynkuet<\/strong>, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-dual-action-mechanism-explains-potent-symptom-relief\">Dual\u2010Action Mechanism Explains Potent Symptom Relief<\/h4>\n\n\n\n<p>Elnizanetant targets both <strong>neurokinin\u20111 (NK\u20111)<\/strong> and <strong>neurokinin\u20113 (NK\u20113)<\/strong> receptors, blocking the signaling of Substance\u202fP and neurokinin\u202fB (NKB). Research shows that KNDy neurons \u2013 comprising kisspeptin, NKB, and dynorphin \u2013 over\u2011activate when estrogen levels drop during menopause, disrupting the hypothalamic thermoregulatory circuit. By dampening this hyperactivity, the drug reduces hot flashes, sweating, and the sleep\u2011disturbing effects that plague most women in transition.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-competitive-landscape-a-new-option-for-a-20-b-market\">Competitive Landscape: A New Option for a $20\u202fB Market<\/h4>\n\n\n\n<p>The global market for menopause symptom relief is projected to exceed <strong>$20\u202fbillion<\/strong> by 2028. Existing first\u2011line agents include selective estrogen\u2011receptor modulators (SERMs) and selective progesterone\u2011receptor modulators (SPRMs), yet many patients seek alternatives that sidestep hormone therapy. Elinzanetant\u2019s monthly\u2011subcutaneous dosing and dual\u2011target profile could differentiate Bayer from established players such as Pfizer, Roche, and Lilly, who currently offer hormone\u2011based solutions.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-global-rollout-and-future-approval-pathways\">Global Rollout and Future Approval Pathways<\/h4>\n\n\n\n<p>Beyond the United States, <strong>Lynkuet<\/strong> is already approved in Australia, Canada, the United Kingdom, and Switzerland, and the drug is pending acceptance in the European Union. Bayer has filed for approval in Japan, South Korea, and Brazil, positioning the product for a full\u2011world commercial launch.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-investor-takeaway\">Investor Takeaway<\/h4>\n\n\n\n<p>Bayer\u2019s entry into the VMS arena expands its therapeutic footprint beyond oncology and cardiovascular indications. The dual\u2011NK mechanism, combined with strong safety data and an attractive dosing schedule, will likely strengthen the company\u2019s patent moat and open new revenue streams in an aging female population. Investors should monitor post\u2011marketing uptake, real\u2011world effectiveness data, and the speed of EU clearance as key catalysts moving forward.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45329,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,15],"class_list":["post-45328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45328\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS\" \/>\n<meta property=\"og:description\" content=\"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45328\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T14:14:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T14:14:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS\",\"datePublished\":\"2025-10-30T14:14:55+00:00\",\"dateModified\":\"2025-10-30T14:14:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3004-2.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45328#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45328\",\"name\":\"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3004-2.webp\",\"datePublished\":\"2025-10-30T14:14:55+00:00\",\"dateModified\":\"2025-10-30T14:14:56+00:00\",\"description\":\"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45328\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3004-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3004-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45328#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45328","og_locale":"en_US","og_type":"article","og_title":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS","og_description":"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.","og_url":"https:\/\/flcube.com\/?p=45328","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T14:14:55+00:00","article_modified_time":"2025-10-30T14:14:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45328#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45328"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS","datePublished":"2025-10-30T14:14:55+00:00","dateModified":"2025-10-30T14:14:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45328"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45328#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","keywords":["Bayer","ETR: BAYN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45328#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45328","url":"https:\/\/flcube.com\/?p=45328","name":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45328#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45328#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","datePublished":"2025-10-30T14:14:55+00:00","dateModified":"2025-10-30T14:14:56+00:00","description":"Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval for elnizanetant, the first dual neurokinin (NK) receptor antagonist to treat moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause. Commercially branded as Lynkuet, the drug is slated for U.S. launch in November\u202f2025, following the swift clearance of its pivotal trials and a thorough safety review.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45328#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45328"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45328#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","width":1080,"height":608,"caption":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45328#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3004-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45328"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45328\/revisions"}],"predecessor-version":[{"id":45330,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45328\/revisions\/45330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45329"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}